Isis Pharmaceuticals, Inc. (Isis) is a Ribonucleic acid-targeted (RNA-targeted) drug discovery and development company. The Company is focused to discover and develop antisense drugs. The antisense drugs are used to treat a range of diseases, including cardiovascular, metabolic, severe and rare diseases, including neurological disorders and cancer. ISIS-APOCIII is a drug indicated to to treat patients with high triglyceride levels, including patients with a genetic condition called familial chylomicronemia syndrome (FCS) and patients with partial lipodystrophy. In addition to ISIS-APOCIII, it is also evaluating ISIS-TTR and ISIS-SMN in Phase III studies. Its lipid-lowering product, KYNAMRO (mipomersen sodium) injection, is on the market in the United States for patients with homozygous familial hypercholesterolemia (HoFH).